Merck to Present One-Year BRUNELLO Phase 2b/3 Results
Merck said it will present one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103) in adults with diabetic macular edema at AAO 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck says remigromig meets primary endpoint in pivotal BRUNELLO trial for diabetic macular edema
Merck reported topline results from the pivotal Phase 2b/3 BRUNELLO trial of remigromig in adults with diabetic macular edema. Year-one data will be presented Oct. 10 at the American Academy of Ophthalmology Annual Meeting. Both remigromig doses met the primary goal, matching ranibizumab on vision outcomes over 52 week
Merck’s Remigromig, a Tri — specific Agonist of the Wingless — related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
For best results when printing this announcement, please click on link below: Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema Remigromig demonstrated non-inferiority to